Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiotherapy for resectable pancreatic cancer: A prospective, open‐label, phase II study

Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiotherapy for resectable pancreatic cancer: A prospective, open‐label, phase II study

Abstract Background Resectable pancreatic cancer (RPC) is potentially resectable on admission, and the impact of neoadjuvant therapy on these tumors is controversial. Moreover, the safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiation the...

ver descrição completa

Detalhes bibliográficos
Principais autores: Toshihiko Masui, Kazuyuki Nagai, Takayuki Anazawa, Yosuke Kasai, Akitada Yogo, Michio Yoshimura, Takashi Mizowaki, Norimitsu Uza, Akihisa Fukuda, Shigemi Matsumoto, Masashi Kanai, Hiroyoshi Isoda, Yoshiya Kawaguchi, Shinji Uemoto, Etsuro Hatano
Formato: Artigo
Idioma:English
Publicado em: Wiley 2023-09-01
coleção:Cancer Medicine
Assuntos:
chemoradiotherapy
IMRT
intensity‐modulated radiotherapy
neoadjuvant therapy
pancreatic cancer
surgery
Acesso em linha:https://doi.org/10.1002/cam4.6470

Internet

https://doi.org/10.1002/cam4.6470

Registros relacionados